keyword
MENU ▼
Read by QxMD icon Read
search

Discontinuation anti-TNF

keyword
https://www.readbyqxmd.com/read/28221250/factors-associated-with-discontinuation-of-anti-tnf-inhibitors-among-persons-with-ibd-a-population-based-analysis
#1
Laura E Targownik, Aruni Tennakoon, Stella Leung, Lisa M Lix, Zoann Nugent, Harminder Singh, Charles N Bernstein
INTRODUCTION: Antitumor necrosis factor (anti-TNF) medications are known to be highly efficacious in persons with moderate-to-severe inflammatory bowel disease (IBD). There is a paucity of data from population-based sources to elucidate persistence with these medications in the general population of IBD. Discontinuation of anti-TNF therapy is a marker of lack of effectiveness, intolerance, and patient/physician practice preferences. METHODS: We identified all persons with IBD in Manitoba who were dispensed infliximab (IFX) and adalimumab (ADA) between 2001 and 2014...
March 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28211161/psoriasis-and-psoriasiform-eruptions-in-pediatric-patients-with-inflammatory-bowel-disease-treated-with-anti-tumor-necrosis-factor-alpha-agents
#2
Joshua B Eickstaedt, Luke Killpack, Jeanne Tung, Dawn Davis, Jennifer L Hand, Megha M Tollefson
BACKGROUND: Anti-tumor necrosis factor alpha (TNF-α) agents are used to treat a variety of autoimmune and inflammatory conditions, including psoriasis. Paradoxically, numerous reports have documented new-onset or exacerbation of psoriasis or psoriasiform skin lesions (PSO) in patients treated with these agents for conditions other than PSO-particularly in adults with inflammatory bowel disease (IBD). Not much is known regarding similar cases in children. METHODS: A retrospective chart review was performed on children younger than 19 years of age with IBD seen at the Mayo Clinic between 2003 and 2015 who developed new-onset or recurrent PSO while undergoing anti-TNF-α therapy...
February 17, 2017: Pediatric Dermatology
https://www.readbyqxmd.com/read/28184367/novel-immunotherapies-for-autoimmune-hepatitis
#3
REVIEW
Shamir Cassim, Marc Bilodeau, Catherine Vincent, Pascal Lapierre
Autoimmune hepatitis (AIH) is a multifactorial autoimmune disease of unknown pathogenesis, characterized by a loss of immunological tolerance against liver autoantigens resulting in the progressive destruction of the hepatic parenchyma. Current treatments are based on non-specific immunosuppressive drugs. Although tremendous progress has been made using specific biological agents in other inflammatory diseases, progress has been slow to come for AIH patients. While current treatments are successful in the majority of patients, treatment discontinuation is difficult to achieve, and relapses are frequent...
2017: Frontiers in Pediatrics
https://www.readbyqxmd.com/read/28179619/rituximab-can-induce-remission-in-a-patient-with-ankylosing-spondylitis-who-failed-anti-tnf-%C3%AE-agent
#4
Fahmi AlDhaheri, Talal Almteri, Naji Dwid, Ahd Majdali, Nahed Janoudi, Hani Almoallim
BACKGROUND Ankylosing spondylitis (AS) is a chronic inflammatory disease that predominantly affects the axial skeleton. The ability of anti-TNF-α agents to reduce disease activity in patients with axial spondyloarthritis (axSpA), including AS, has been demonstrated in multiple randomized trials and several meta-analyses. Reports on the efficacy of rituximab in treatment of AS have described good results. We report on a patient with AS who failed anti-TNF-α therapy but showed good clinical improvement with rituximab therapy...
February 9, 2017: American Journal of Case Reports
https://www.readbyqxmd.com/read/28175212/p611-relapse-risk-and-predictors-for-relapse-in-a-real-life-cohort-of-ibd-patients-after-discontinuation-of-anti-tnf-therapy
#5
S Bots, S Kuin, C Ponsioen, G van den Brink, M Löwenberg, G D'Haens
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28175204/p634-long-term-risk-of-relapse-after-anti-tnf-discontinuation-based-on-mucosal-healing-in-inflammatory-bowel-disease
#6
J M García Ortíz, M Sáenz Gallo, C Trigo Salado, M D De La Cruz Ramirez, J L Marquez Galan, J M Herrera Justiniano, J M Bozada García, E Leo Carnerero
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28175130/p462-long-term-outcomes-of-anti-tnf-therapy-discontinuation-in-patients-with-penetrating-crohn-s-disease
#7
M Gompertz, E Ricart, I Ordás, I Alfaro, A Lόpez, M Gallego, R Barastegui, A Giner, A Vara, M Masamunt, J Panés
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28172903/p388-risk-of-relapse-in-ulcerative-colitis-patients-in-clinical-remission-with-combination-therapy-anti-tnf-and-azathioprine-after-immunomodulator-discontinuation
#8
C Mihai, M Dranga, O Gavrilescu, I Ungureanu, A Didita, A M Chiosa, A Savin, I Popa, R Popa, O Jigaranu, C Cijevschi-Prelipcean
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28125554/o-006-rapid-infliximab-infusion-in-children-with-inflammatory-bowel-disease-a-multi-center-north-american-experience
#9
Wael El-Matary, Charles Samson, Alisa Crim, Sabina Ali, Andrew Grossman
BACKGROUND: Infusions of infliximab (IFX), a chimeric monoclonal antibody against tumor necrosis factor alpha (TNF-α) used to treat inflammatory bowel disease (IBD), can lead to development of anti-IFX antibodies (ATI), increasing risk of subsequent infusion reactions (IRs). IRs have been reported in as many as 5% of infusions and up to 10% to 20% of patients. The safety of rapid IFX infusion has been under-evaluated in children. In a multi-center study, the incidence of IRs associated with rapid infusion of IFX was examined...
February 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28089625/azathioprine-for-refractory-ulcerative-proctitis-a-retrospective-multicenter-study
#10
Anne-Laure Mallet, Guillaume Bouguen, Guillaume Conroy, Xavier Roblin, Jean-Bernard Delobel, Jean-François Bretagne, Laurent Siproudhis, Laurent Peyrin-Biroulet
BACKGROUND: Efficacy of azathioprine (AZA) in refractory ulcerative proctitis (UP) is unknown. METHODS: All patients treated with AZA for refractory UP in three referral centers between 2002 and 2012 were included. "Treatment success" in the long-term was defined as the absence of colectomy during follow-up, no need for anti-TNF during follow-up, no ongoing systemic steroids use, no adverse event leading to AZA withdrawal, and clinically quiescent disease at last follow-up...
December 13, 2016: Digestive and Liver Disease
https://www.readbyqxmd.com/read/28010883/effectiveness-and-drug-survival-of-tnf-inhibitors-in-the-treatment-of-psoriatic-arthritis-a-prospective-cohort-study
#11
Kalle Aaltonen, Arto Heinonen, Jaana Joensuu, Pinja Parmanne, Anna Karjalainen, Tuire Varjolahti-Lehtinen, Toini Uutela, Maija Puurtinen-Vilkki, Leena Arstila, Marja Blom, Tuulikki Sokka, Dan Nordström
BACKGROUND AND OBJECTIVES: Tumor necrosis factor (TNF)-inhibitors are used to treat psoriatic arthritis (PsA), but only a limited number of observational studies on this subject have been published thus far. The aim of this research was to analyze the effectiveness and drug survival of TNF-inhibitors in the treatment of PsA. METHODS: PsA patients identified from the National Register for Biologic Treatment in Finland (ROB-FIN) starting their first, second, or third TNF-inhibitor treatment between 2004 and 2014 were included...
September 16, 2016: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/27995400/adalimumab-maintenance-treatment-in-ulcerative-colitis-outcomes-by-prior-anti-tnf-use-and-efficacy-of-dose-escalation
#12
Carlos Taxonera, Eva Iglesias, Fernando Muñoz, Marta Calvo, Manuel Barreiro-de Acosta, David Busquets, Xavier Calvet, Antonio Rodríguez, Ramón Pajares, Javier P Gisbert, Pilar López-Serrano, José Luís Pérez-Calle, Ángel Ponferrada, Cristóbal De la Coba, Fernando Bermejo, María Chaparro, David Olivares, Cristina Alba, Ignacio Fernández-Blanco
BACKGROUND: The impact of prior anti-TNF use on "real-life" outcomes of adalimumab therapy in ulcerative colitis (UC) is not well known. AIM: To compare the influence of prior anti-TNF use on the outcomes of adalimumab maintenance treatment in UC patients. We also assessed the effectiveness of adalimumab dose escalation. METHODS: This retrospective multicenter cohort study included consecutive UC who advanced to an adalimumab maintenance regimen...
December 19, 2016: Digestive Diseases and Sciences
https://www.readbyqxmd.com/read/27992009/development-of-exclusively-cutaneous-sarcoidosis-in-patient-with-rheumatoid-arthritis-during-treatment-with-etanercept
#13
Marcella Amaral Horta Barbosa Vieira, Maria Isabel Ramos Saraiva, Larissa Karine Leite da Silva, Rafael Cavanellas Fraga, Priscila Kakizaki, Neusa Yuriko Sakai Valente
We report the case of a patient with rheumatoid arthritis who, after 2 months of treatment with etanercept, showed disseminated asymptomatic violaceous papules. Biopsy of the skin lesion showed chronic granulomatous dermatitis with negative staining for fungi and acid-fast bacilli (AFB). After discontinuation of etanercept, the patient's condition improved. Although apparently paradoxical, cases of cutaneous and systemic sarcoidosis after anti-TNF medications have been reported in the literature, with very few cases presenting exclusive cutaneous involvement...
November 2016: Revista da Associação Médica Brasileira
https://www.readbyqxmd.com/read/27990383/biologics-use-in-indian-psoriasis-patients
#14
Murlidhar Rajagopalan, Asit Mital
The biologics currently in use for psoriasis in India are etanercept, infliximab and recently introduced itolizumab and secukinumab. Biosimilars, expected to play a significant role in psoriasis management in future, have also been available for the last few years. Patients with psoriasis may be considered eligible to receive treatment with any of the licensed biologic interventions when they fulfill the eligibility criteria. The decision to proceed with treatment must be made in collaboration with the patient and include a careful assessment of the associated risks and benefits...
November 2016: Indian Dermatology Online Journal
https://www.readbyqxmd.com/read/27982551/use-of-biological-treatments-in-patients-with-hidradenitis-suppurativa
#15
Gemma Martin-Ezquerra, Emili Masferrer, Ramon M Pujol
Pilosebaceous unit occlusion and secondary inflammatory perifollicular lympho-histiocytic infiltration seem to be the underlying etiopathogenic mechanisms giving rise to hidradenitis suppurativa (HS). Increased levels of tumor necrosis factor (TNF)-alpha and other cytokines such as interleukins 12 and 23 (IL12/23) and interleukins 10 and 17 have been observed in HS lesional skin. Biological drugs have been reported to be effective for HS, but the level and duration of the response are quite variable. Among anti-TNF drugs, adalimumab and infliximab are the drugs that seem to obtain better results in HS...
December 16, 2016: Giornale Italiano di Dermatologia e Venereologia: Organo Ufficiale, Società Italiana di Dermatologia e Sifilografia
https://www.readbyqxmd.com/read/27974094/long-term-safety-of-anti-tnf-agents-on-the-liver-of-patients-with-spondyloarthritis-and-potential-occult-hepatitis-b-viral-infection-an-observational-multicentre-study
#16
Chiara Giannitti, Giuseppe Lopalco, Antonio Vitale, Donato Rigante, Maria Grazia Anelli, Marta Fabbroni, Stefania Manganelli, Mauro Galeazzi, Bruno Frediani, Michele Barone, Giovanni Lapadula, Florenzo Iannone, Luca Cantarini
OBJECTIVES: The aim of the study was to retrospectively evaluate the long-term safety profile of anti-tumour necrosis factor (TNF)-α agents on the liver of patients with spondyloarthritis (SpA) and a previously resolved hepatitis B virus (HBV) infection. METHODS: Medical records from 992 consecutive outpatients receiving anti-TNF-α therapy between 2007 and 2015 were retrospectively reviewed. HBV infection was assessed evaluating HBV surface antigen (HBsAg), antibodies to HBsAg (anti-HBs), antibodies to hepatitis B core (anti-HBc), and HBV-DNA levels...
December 9, 2016: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/27958281/evolution-after-anti-tnf-discontinuation-in-patients-with-inflammatory-bowel-disease-a-multicenter-long-term-follow-up-study
#17
M J Casanova, M Chaparro, V García-Sánchez, O Nantes, E Leo, M Rojas-Feria, A Jauregui-Amezaga, S García-López, J M Huguet, F Arguelles-Arias, M Aicart, I Marín-Jiménez, M Gómez-García, F Muñoz, M Esteve, L Bujanda, X Cortés, J Tosca, J R Pineda, M Mañosa, J Llaó, J Guardiola, I Pérez-Martínez, C Muñoz, Y González-Lama, J Hinojosa, J M Vázquez, M P Martinez-Montiel, G E Rodríguez, R Pajares, M F García-Sepulcre, A Hernández-Martínez, J L Pérez-Calle, B Beltrán, D Busquets, L Ramos, F Bermejo, J Barrio, M Barreiro-de Acosta, O Roncedo, X Calvet, D Hervías, F Gomollón, M Domínguez-Antonaya, G Alcaín, B Sicilia, C Dueñas, A Gutiérrez, R Lorente-Poyatos, M Domínguez, S Khorrami, C Muñoz, C Taxonera, A Rodríguez-Pérez, A Ponferrada, M Van Domselaar, M L Arias-Rivera, O Merino, E Castro, J M Marrero, M Martín-Arranz, B Botella, L Fernández-Salazar, D Monfort, V Opio, A García-Herola, M Menacho, P Ramírez-de la Piscina, D Ceballos, P Almela, M Navarro-Llavat, V Robles-Alonso, A B Vega-López, I Moraleja, M T Novella, C Castaño-Milla, A Sánchez-Torres, J M Benítez, C Rodríguez, L Castro, E Garrido, E Domènech, E García-Planella, J P Gisbert
OBJECTIVES: The aims of this study were to assess the risk of relapse after discontinuation of anti-tumor necrosis factor (anti-TNF) drugs in patients with inflammatory bowel disease (IBD), to identify the factors associated with relapse, and to evaluate the overcome after retreatment with the same anti-TNF in those who relapsed. METHODS: This was a retrospective, observational, multicenter study. IBD patients who had been treated with anti-TNFs and in whom these drugs were discontinued after clinical remission was achieved were included...
January 2017: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/27939407/higher-body-mass-index-and-anti-drug-antibodies-predict-the-discontinuation-of-anti-tnf-agents-in-korean-patients-with-axial-spondyloarthritis
#18
Jiwon Hwang, Hye-Mi Kim, Hyemin Jeong, Jaejoon Lee, Joong Kyong Ahn, Eun-Mi Koh, Eun-Suk Kang, Hoon-Suk Cha
OBJECTIVE: The development of anti-drug antibodies (ADAbs) against tumor necrosis factor (TNF) inhibitors is a likely explanation for the failure of TNF-inhibitors in patients with spondyloarthritis (SpA). Our study determined the existence and clinical implications of ADAbs in axial SpA patients. METHODS: According to the Assessment of SpondyloArthritis International Society classification criteria for axial SpA, patients treated with adalimumab or infliximab were recruited consecutively...
November 15, 2016: Revista Brasileira de Reumatologia
https://www.readbyqxmd.com/read/27937079/long-term-follow-up-of-patients-with-tubulointerstitial-nephritis-and-uveitis-tinu-syndrome
#19
Bianka Sobolewska, Tarek Bayyoud, Christoph Deuter, Deshka Doycheva, Manfred Zierhut
PURPOSE: To evaluate the response to treatment in patients with tubulointerstitial nephritis and uveitis (TINU) syndrome over a long-term follow-up period. METHODS: Nine patients with TINU syndrome were retrospectively reviewed. The mean follow-up was 54.8 months (range: 24-133 months). RESULTS: The mean number of recurrences per year declined from 1.7 in the 1st year to 0.66 in the 2nd year of treatment. The ocular inflammation responded to local corticosteroids in two patients, systemic corticosteroids in two patients, immunosuppressive therapy in four patients, and anti-TNF-α blocking agent in one patient...
December 12, 2016: Ocular Immunology and Inflammation
https://www.readbyqxmd.com/read/27849614/epipolymorphisms-associated-with-the-clinical-outcome-of-autoimmune-arthritis-affect-cd4-t-cell-activation-pathways
#20
Roberto Spreafico, Maura Rossetti, John W Whitaker, Wei Wang, Daniel J Lovell, Salvatore Albani
Multifactorial diseases, including autoimmune juvenile idiopathic arthritis (JIA), result from a complex interplay between genetics and environment. Epigenetic mechanisms are believed to integrate such gene-environment interactions, fine-tuning gene expression, and possibly contributing to immune system dysregulation. Although anti-TNF therapy has strongly increased JIA remission rates, it is not curative and up to 80% of patients flare upon treatment withdrawal. Thus, a crucial unmet medical and scientific need is to understand the immunological mechanisms associated with remission or flare to inform clinical decisions...
November 29, 2016: Proceedings of the National Academy of Sciences of the United States of America
keyword
keyword
61555
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"